Kudzu root extract and binge drinking: 12-week placebo-controlled trial infographic, Ep. 1320

In a 12-week randomized, placebo-controlled trial, adults with alcohol use disorder who took a standardized kudzu extract before expected heavy drinking had fewer binge-drinking days than those on placebo. The kudzu group went from about 2.2 to 1.4 binge days a week; the placebo group barely changed (2.2 to 2.1). That works out to about 27% fewer binge days than placebo, a real but narrow result (p = 0.049).

One proposed explanation involves puerarin, kudzu’s main isoflavone: earlier research suggests it may change how the first drinks are felt, so people pace themselves. This trial measured drinking, not the mechanism.

The study at a glance

  • Design: phase 2b, randomized, double-blind, placebo-controlled
  • Participants: 120 adults with alcohol use disorder who binge drink (60 kudzu, 60 placebo), at a single site (San Francisco Department of Public Health)
  • What they took: 2 g standardized kudzu extract or a matching placebo, at least 2.5 hours before expected heavy drinking (as needed, not daily)
  • Also: brief weekly counseling in both groups
  • Length: 12 weeks, with follow-up three months after stopping
  • Primary result: about 27% fewer binge-drinking days than placebo (incidence rate ratio 0.73; 95% CI 0.54 to 0.99; p = 0.049)
  • Three months after stopping: still about 32% fewer binge days than placebo (incidence rate ratio 0.68; 95% CI 0.47 to 0.97; p = 0.036); why the difference lasted is not known
  • Lab tests: in the main (intention-to-treat) analysis, neither urine EtG nor blood PEth differed significantly between groups; PEth differed only in a secondary analysis of people who took the capsules at least 2.7 days a week. The main result rests on self-reported binge days.
  • Safety: side effects were no more common than with placebo, and no serious side effects were linked to kudzu. Earlier laboratory research found balance and reaction time didn’t worsen when kudzu was taken with alcohol; those were not outcomes of this 12-week trial, which was also too small and short to establish long-term safety.

In this episode:

  • Meet kudzu: the root, its isoflavones, and how it has been studied
  • Myth check: why kudzu is not an “aversion pill” that makes you ill
  • The follow-up surprise: fewer binge days three months after the capsules stopped
  • What the lab tests (EtG, PEth) did and didn’t show, and why the main result was a close call (p = 0.049)
  • Plan vs paper: what the registered protocol promised and what was reported
  • Reality check: 120 adults, one study, not yet confirmed by an independent team

What this study can’t tell us

  • It is one mid-stage (phase 2b) trial at a single site; larger trials are needed to confirm it.
  • Binge days were self-reported, and the main result was borderline (the confidence interval nearly reaches no effect).
  • Both groups had counseling, so it doesn’t show what kudzu would do on its own.
  • The standardized study extract is not the same as store-bought kudzu products, which vary.
  • Participants had alcohol use disorder; the findings don’t automatically apply to everyone who drinks.

Kudzu is not an established treatment for alcohol use disorder, and it is not a free pass to drink more. If alcohol is a concern for you, talk with a doctor; support and proven treatments exist.

ClinicalNews has followed kudzu research since 2014: see our earlier coverage of the 2012 McLean Hospital study.

This is educational content, not medical advice. Do not start a supplement without talking to your doctor, especially if you take other medications.

📄 Study: Santos G-M, Coffin P, Dunham A, et al. Targeted Use of Kudzu for Binge Drinking Among Adults With Alcohol Use Disorder: A Phase 2b Randomized Trial. Am J Psychiatry (2026). doi:10.1176/appi.ajp.20251354
📋 Trial registry: ClinicalTrials.gov NCT03709043
🤝 Created together: Ralph Turchiano (VHFILM) × Claude (Anthropic), reviewed against the paper with ChatGPT (OpenAI)

#Kudzu #BingeDrinking #AlcoholResearch #ClinicalTrial

Ralph Turchiano

By Ralph Turchiano

I have a strong affinity for the sciences which led me to create my sites. My compulsion for the past decade has been reviewing literally every peer-reviewed research article. Which can easily be validated by following my posts. To me, science is where the real news is, as it will mold our destiny beyond that of politics or economics. ;-)

Leave a Reply